SMAD4 provides a barrier to metastatic progression in PTEN-null mouse prostates, and when deleted, it drives highly aggressive prostate cancer that metastasizes to the lymph node and lung (Ding et al., 2011). Here, SMAD4 is linked to prostate cancer.